Dexamethasone
Cross-source consensus on Dexamethasone from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Benefits
Comparisons
Background
Evidence quality
Highlighted claims
- The RECOVERY trial was a prospective RCT evaluating dexamethasone 6 mg/day in hospitalized COVID-19 patients; it was stopped early due to a clear mortality benefit. — COVID-19 ICU Treatment: Clinical Updates and Protocols
- Dexamethasone produced approximately 35% relative risk reduction in mortality among mechanically ventilated COVID-19 patients — an unusually large effect for a viral respiratory failure ICU study. — COVID-19 ICU Treatment: Clinical Updates and Protocols
- The RECOVERY trial findings were adopted rapidly across institutions even before full peer review, based on a preprint posted to medRxiv. — COVID-19 ICU Treatment: Clinical Updates and Protocols
- Dexamethasone is purely synthetic with minimal mineralocorticoid activity, unlike other corticosteroids that vary in their tendency to cause sodium and water retention. — COVID-19 ICU Treatment: Clinical Updates and Protocols
- All glucocorticoids share an anti-inflammatory mechanism of benefit, but whether differences in mineralocorticoid activity affect COVID-19 outcomes specifically is unknown. — COVID-19 ICU Treatment: Clinical Updates and Protocols
- Substituting methylprednisolone at equivalent doses is reasonable if dexamethasone is unavailable, but outcomes are expected to be similar rather than confirmed. — COVID-19 ICU Treatment: Clinical Updates and Protocols